These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

247 related articles for article (PubMed ID: 31552162)

  • 1. The Flick of a Switch: Conferring Survival Advantage to Breast Cancer Stem Cells Through Metabolic Plasticity.
    Walsh HR; Cruickshank BM; Brown JM; Marcato P
    Front Oncol; 2019; 9():753. PubMed ID: 31552162
    [TBL] [Abstract][Full Text] [Related]  

  • 2. ALDH1A3 is the switch that determines the balance of ALDH
    Fernando W; Cruickshank BM; Arun RP; MacLean MR; Cahill HF; Morales-Quintanilla F; Dean CA; Wasson MD; Dahn ML; Coyle KM; Walker OL; Power Coombs MR; Marcato P
    Oncogene; 2024 Oct; 43(43):3151-3169. PubMed ID: 39251846
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulation of Metabolic Plasticity in Cancer Stem Cells and Implications in Cancer Therapy.
    Papadaki S; Magklara A
    Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497394
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting.
    Walker OL; Dahn ML; Power Coombs MR; Marcato P
    Front Oncol; 2021; 11():791696. PubMed ID: 35127497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular pathology underlying the robustness of cancer stem cells.
    Yoshida GJ; Saya H
    Regen Ther; 2021 Jun; 17():38-50. PubMed ID: 33869685
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas.
    Martin-Castillo B; Lopez-Bonet E; Cuyàs E; Viñas G; Pernas S; Dorca J; Menendez JA
    Oncotarget; 2015 Oct; 6(32):32317-38. PubMed ID: 26474458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cancer Stem Cell Metabolism and Potential Therapeutic Targets.
    Snyder V; Reed-Newman TC; Arnold L; Thomas SM; Anant S
    Front Oncol; 2018; 8():203. PubMed ID: 29922594
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic Reprogramming and Dependencies Associated with Epithelial Cancer Stem Cells Independent of the Epithelial-Mesenchymal Transition Program.
    Aguilar E; Marin de Mas I; Zodda E; Marin S; Morrish F; Selivanov V; Meca-Cortés Ó; Delowar H; Pons M; Izquierdo I; Celià-Terrassa T; de Atauri P; Centelles JJ; Hockenbery D; Thomson TM; Cascante M
    Stem Cells; 2016 May; 34(5):1163-76. PubMed ID: 27146024
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oncogenic Metabolism Acts as a Prerequisite Step for Induction of Cancer Metastasis and Cancer Stem Cell Phenotype.
    Lee SY; Ju MK; Jeon HM; Lee YJ; Kim CH; Park HG; Han SI; Kang HS
    Oxid Med Cell Longev; 2018; 2018():1027453. PubMed ID: 30671168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Cancer Stem Cell Redox Metabolism to Enhance Therapy Responses.
    Luo M; Wicha MS
    Semin Radiat Oncol; 2019 Jan; 29(1):42-54. PubMed ID: 30573183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer stem-like cells enriched with CD29 and CD44 markers exhibit molecular characteristics with epithelial-mesenchymal transition in squamous cell carcinoma.
    Geng S; Guo Y; Wang Q; Li L; Wang J
    Arch Dermatol Res; 2013 Jan; 305(1):35-47. PubMed ID: 22740085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trailblazing perspectives on targeting breast cancer stem cells.
    Li J; Qi D; Hsieh TC; Huang JH; Wu JM; Wu E
    Pharmacol Ther; 2021 Jul; 223():107800. PubMed ID: 33421449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conflicting metabolic alterations in cancer stem cells and regulation by the stromal niche.
    Yasuda T; Ishimoto T; Baba H
    Regen Ther; 2021 Jun; 17():8-12. PubMed ID: 33598509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSCs in Breast Cancer-One Size Does Not Fit All: Therapeutic Advances in Targeting Heterogeneous Epithelial and Mesenchymal CSCs.
    Sulaiman A; McGarry S; Han X; Liu S; Wang L
    Cancers (Basel); 2019 Aug; 11(8):. PubMed ID: 31394796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer stem cells and intrinsic subtypes: controversies rage on.
    Nakshatri H; Srour EF; Badve S
    Curr Stem Cell Res Ther; 2009 Jan; 4(1):50-60. PubMed ID: 19149630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
    BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Energy metabolism in cancer stem cells.
    Zhu X; Chen HH; Gao CY; Zhang XX; Jiang JX; Zhang Y; Fang J; Zhao F; Chen ZG
    World J Stem Cells; 2020 Jun; 12(6):448-461. PubMed ID: 32742562
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of breast cancer stem cell features.
    Czerwinska P; Kaminska B
    Contemp Oncol (Pozn); 2015; 19(1A):A7-A15. PubMed ID: 25691826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression distribution of cancer stem cells, epithelial to mesenchymal transition, and telomerase activity in breast cancer and their association with clinicopathologic characteristics.
    Makki J; Myint O; Wynn AA; Samsudin AT; John DV
    Clin Med Insights Pathol; 2015; 8():1-16. PubMed ID: 25624778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer Stem Cell Plasticity - A Deadly Deal.
    Thankamony AP; Saxena K; Murali R; Jolly MK; Nair R
    Front Mol Biosci; 2020; 7():79. PubMed ID: 32426371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.